Brainlab and Precision NeuroMed have formed a strategic partnership to develop an AI-enabled treatment planning platform for convection enhanced delivery (CED) to the brain. Brainlab has taken an equity stake in the clinical-stage biotechnology company as part of the collaboration. The partnership aims to create a cloud-based CED Treatment Planning System that combines Brainlab's medical imaging expertise with Precision NeuroMed's molecular flow simulation software. The platform will use advanced imaging and AI-driven optimisation to personalise drug distribution, overcoming blood-brain barrier limitations that restrict most systemically administered drugs. Initial development will focus on supporting Precision NeuroMed's lead drug, PNM-201, for recurrent glioblastoma. The companies plan to expand the platform to enable delivery of therapies for epilepsy, Parkinson's disease, Alzheimer's disease and ALS.

Lovell Government Services, a Service-Disabled Veteran-Owned Small Business, has been awarded a Patient Monitoring and Capital Equipment contract with Brainlab, expanding access to advanced surgical technology across VA and DoD facilities. The partnership adds capital equipment and patient monitoring solutions to Lovell's federal portfolio, which previously focused on consumables. Brainlab, a digital medical technology company operating in 4,000 hospitals across 120 countries, first partnered with Lovell in 2024. The company develops integrated hardware and software for surgery and radiation therapy. The contract builds on Lovell's strong 2025 performance, which included over $100 million in sales, expanded Defence Logistics Agency Electronic Catalog access, and pharmaceutical distribution accreditation. Founded in 2013, Lovell has appeared four times on the Inc. 5000 list.